{"id":"W4403267451","doi":"10.1016/j.isci.2024.111108","title":"Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"Neurological Disease Mechanisms and Treatments","field":"Neuroscience","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"Agencia Estatal de Investigación; Instituto de Salud Carlos III; European Research Council; Fonds de Recherche du Québec - Santé; Institut national de la recherche scientifique; Xunta de Galicia; Consellería de Economía, Emprego e Industria, Xunta de Galicia; Ministerio de Ciencia e Innovación; Fundación Mutua Madrileña; European Regional Development Fund; European Commission; Federación Española de Enfermedades Raras; EuroNanoMed III","keywords":"Transaminase; Glutamate receptor; Recombinant DNA; Stroke (engine); Medicine; Citrate synthase; Aspartate transaminase; Biochemistry; Pharmacology; Chemistry; Internal medicine; Neuroscience; Biology; Enzyme; Alkaline phosphatase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002146138,0.001101384,0.001565971,0.0006007989,0.0003534233,0.0007894968,0.0008796515,0.0006255112,0.001361739],"category_scores_gemma":[0.0008113377,0.0002891777,0.0005526308,0.0004368255,0.0006473273,0.0005326079,0.0003037856,0.001452935,0.0006559317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004479418,"about_ca_system_score_gemma":0.001255796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007819255,"about_ca_topic_score_gemma":0.001402037,"domain_scores_codex":[0.9994599,0.0002147836,0.00005225587,0.0000668422,0.0001088781,0.00009720569],"domain_scores_gemma":[0.9995497,0.00005914323,0.00009516189,0.00007577401,0.0001092818,0.000110894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01277222,0.01613204,0.0008165623,0.001369546,0.0003824122,0.0005708205,0.0002987497,0.001929215,0.9329737,0.0006873567,0.001910483,0.03015698],"study_design_scores_gemma":[0.004863265,0.2254422,0.005612776,0.0002399011,0.0009044055,0.001277982,0.0001674402,0.003254568,0.7400967,0.0006827169,0.01740932,0.00004873923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716045,0.008982304,0.01185423,0.0005729796,0.0003631626,0.002549824,0.001392657,0.000186639,0.002493696],"genre_scores_gemma":[0.9703115,0.01189911,0.01012149,0.0002448391,0.0001526285,0.001778022,0.002945532,0.0000626437,0.002484132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002146138,"threshold_uncertainty_score":0.01135004,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08261990111822587,"score_gpt":0.3563263450952718,"score_spread":0.2737064439770459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}